production of a digestion product with a homogeneous C-terminus.

Applications

- Removal short C-terminal affinity tags from recombinant proteins without leaving any nonnative residues behind when used in combination with MeCPA.
- Identification and removal of disordered residues from the C-termini of native (untagged) proteins, thereby increasing their propensity to crystallize.

Inventors: David Waugh et al. (NCI)
Related Publications: None.
Licensing Status: Available for licensing.
Licensing Contact: Whitney Hastings; 301–451–7337; hastwing@mail.nih.gov.

A DsbC Expression Vector for the Production of Proteins With Disulfide Bonds in the Cytosol of E. coli

Description of Technology: Many proteins of biomedical importance contain disulfide bonds and such proteins are notoriously difficult to produce in Escherichia coli. Current methods to address this problem either export the protein to the periplasmic space, which is a more favorable redox environment for disulfide bond formation, or utilize genetically modified strains of E. coli to alter the redox potential of the cytosol (such as “Origami” or “Shuffle” cells). Unfortunately, these methods generally result in very low yields of the desired product, thus emphasizing the need for a novel method.

The NIH inventors have designed a DsbC expression vector that can be used to improve the yield of correctly oxidized recombinant proteins in the cytosol of E. coli. By overproducing DsbC on a separate plasmid and coexpressing it with carboxypeptidases in the cytosol of E. coli, the inventors were able to increase the amount of properly oxidized, active carboxypeptidases that could be recovered from the cytosol by at least 4-fold. Further, they believe that co-expression of DsbC from a multicopy plasmid vector will also improve the yield of other disulfide bond-containing proteins in E. coli.

Applications: Improving the yield of correctly oxidized recombinant proteins in the cytosol of E. coli.

Advantages: Substantial increase in the amount of active carboxypeptidases recovered from the cytosol and improved yield of disulfide bond-containing proteins in E. coli.

Inventors: David Waugh et al. (NCI)
Related Publications


Licensing Status: Available for licensing.
Licensing Contact: Whitney Hastings; 301–451–7337; hastwing@mail.nih.gov.

Dated: February 16, 2011.

Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2011–4168 Filed 2–23–11; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Laboratory Animal Welfare: Proposed Adoption and Implementation of the Eighth Edition of the Guide for the Care and Use of Laboratory Animals

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health (NIH) requests public comments on (1) NIH’s adoption of the eighth edition of the Guide for the Care and Use of Laboratory Animals (Guide) as a basis for evaluation of institutional programs receiving or proposing to receive Public Health Service (PHS) support for activities involving animals; and (2) if NIH decides to adopt the eighth edition of the Guide, NIH’s proposed implementation plan, which would require that institutions complete at least one semiannual program and facility evaluation using the eighth edition of the Guide as the basis for evaluation by March 31, 2012. NIH will consider comments on (1) the adoption of the Guide and (2) the implementation plan.

DATES: Written comments on the adoption and implementation of the eighth edition of the Guide must be received by NIH within 30 days of the date of publication of this notice in order to be considered.

ADDRESSES: Public comments may be entered at http://grants.nih.gov/grants/olaw/2011guidecomments/add.htm. Comments will be made publicly available. Personally identifiable information (except organizational affiliations) will be removed prior to making comments publicly available.

FOR FURTHER INFORMATION CONTACT:
Office of Laboratory Animal Welfare, Office of Extramural Research, National Institutes of Health, RK1, Suite 360, 6705 Rockledge Drive, Bethesda, MD 20892–7982; telephone 301–496–7163.

SUPPLEMENTARY INFORMATION:

I. Background

The Guide, first published in 1963, is a widely accepted primary reference on animal care and use. Recommendations in the Guide are based on published data, scientific principles, expert opinion, and experience with methods and practices that are determined to be consistent with high quality, humane animal care and use. The eighth edition of the Guide was published in January 2011 following a study by the Institute for Laboratory Animal Research of the National Academy of Sciences (NAS). The NAS study process began in 2008 and followed the requirements of Section 15 of the Federal Advisory Committee Act. The NAS study process is described at the NAS Web site: http://www.nationalacademies.org/studyprocess/index.html.

Since 1985, the PHS Policy on Humane Care and Use of Laboratory Animals, authorized by Public Law 99–158, 42 U.S.C. 289d, and incorporated by reference at 42 CFR 52.8 and 42 CFR 52a.8, has required that institutions receiving PHS support for animal activities base their animal care and use programs on the current edition of the Guide and comply, as applicable, with the Animal Welfare Act and other Federal statutes and regulations relating
to animal activities. The PHS Policy is applicable to all PHS-conducted or -supported activities (including research, research training, experimentation, biological testing, or related purposes) involving live vertebrate animals.

The eighth edition of the Guide contains substantive changes and additions from the previous edition. To gain insight from institutions on the impact of changes to the Guide on their animal care and use programs, NIH seeks comments on whether it should adopt the eighth edition of the Guide. NIH simultaneously proposes an implementation plan for the eighth edition of the Guide and seeks comments on the proposed plan.

The implementation plan proposed by NIH would require institutions to complete at least one semiannual program and facility evaluation, using the eighth edition of the Guide as the basis for evaluation, by March 31, 2012. For such an evaluation to be considered complete by NIH, it would need to include reasonable and specific plans and schedules for corrections of deficiencies where appropriate.

II. Electronic Access


Dated: February 16, 2011.

Francis S. Collins,
Director, National Institutes of Health.

[FR Doc. 2011–4172 Filed 2–23–11; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Interagency Autism Coordinating Committee (IACC) Subcommittee on Safety.

The IACC Subcommittee on Safety will be having a conference call on Wednesday, March 16, 2011. The subcommittee plans to discuss safety issues related to autism spectrum disorder (ASD). This meeting will be accessible to the public through a conference call.

Name of Committee: Interagency Autism Coordinating Committee (IACC).

Type of meeting: Subcommittee on Safety.

Date: March 16, 2011.

Time: 9 a.m. to 10:30 a.m. Eastern Time.

Agenda: The subcommittee plans to discuss safety issues related to autism spectrum disorder.

Place: No in-person meeting; conference call only.


Contact Person: Ms. Lisa Perez, Office of Autism Research Coordination, National Institute of Mental Health, NIH, 6001 Executive Boulevard, MSC 9815a, Rockville, MD 20852, Phone: 301–443–6040, E-mail: IACCPublicInquiries@mail.nih.gov.

Please Note: The conference call will be accessible to the public through a conference call-in number and access code. Members of the public who participate in the conference call will be able to listen to the meeting but will not be heard. If you experience any technical problems with the conference call, please e-mail IACC Tech Support @acerallores.com or call the IACC Technical Support Help Line at 443–680–0098.

Individuals who participate by using this electronic service and who need special assistance, such as captioning of the conference call or other reasonable accommodations, should submit a request to the Contact Person listed on this notice at least 7 days prior to the meeting. Schedule subject to change. Information about the IACC and a registration link for this meeting are available on the Web site: http://www.iacc.hhs.gov.

Dated: February 17, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–4164 Filed 2–23–11; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel;

National Cooperative Drug Discovery Development Groups.

Date: March 10, 2011.

Time: 10 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Vinod Charles, PhD, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6151, MSC 9606, Bethesda, MD 20892–9606, 301–443–1606, charlesv@mail.nih.gov.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; Viral and Host Genetics in NeuroAIDS.

Date: March 16, 2011.

Time: 12 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: David W Miller, PhD, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6140, MSC 9608, Bethesda, MD 20892–9608, 301–443–9734, millerdra@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: February 17, 2011.

Jennifer S. Spaeth
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–4166 Filed 2–23–11; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications.